Opinion

Video

Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial

Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete response rates, favorable safety profile, and potential to offer an effective, bladder-sparing alternative without the toxicity of systemic immunotherapy.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      The BOND-3 trial represents a significant advancement in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer through the use of intravesical cretostimogene. This phase 3, single-arm study focused on high-risk patients and demonstrated promising efficacy and tolerability. The trial enrolled over 100 patients, with a complete response (CR) rate of nearly 75% at any time. Among those who responded, approximately 64% remained in CR at 12 months and over half at 24 months. Notably, cystectomy-free survival at 12 months was around 90%, a meaningful result for patients seeking to preserve their bladders.

      A key strength of the therapy is its safety profile. No grade 3 or 4 adverse events were reported, and most adverse effects were mild and typical of intravesical therapies—bladder spasms, dysuria, urgency, and hematuria. This is particularly important in a population with already compromised bladder health due to prior BCG exposure. Another important aspect of the trial was its inclusion of reinduction for nonresponders, which aligns with current practices in bladder cancer immunotherapy and reflects the drug’s mechanism of action—stimulating both innate and adaptive immune responses. The durability of response, especially in those who did initially respond, suggests sustained immunologic activity even beyond the active treatment period.

      Overall, the findings from BOND-3 highlight cretostimogene as a well-tolerated and effective monotherapy option. The lack of cumulative toxicity with reinduction is particularly noteworthy and differentiates it from repeat BCG therapy, which can exacerbate bladder irritation. These data support cretostimogene’s potential role in future treatment paradigms, especially for patients desiring bladder preservation without systemic immunotherapy. As more follow-up data become available, this agent may help bridge the gap between efficacy and tolerability in a field still searching for optimal bladder-sparing solutions.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.